Ocular Therapeutix, Inc. (OCUL) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ocular Therapeutix’s revenue went from $2M in fiscal 2016 to $52M in fiscal 2025, growth of about 44.5% a year.
Net income in fiscal 2025 was -$266M, a net margin of -511.9%; the best year in this period was 2021 with -$7M.
Over the twelve months to September 30, 2026, revenue was $50M and net income -$327M.
Free cash flow was -$217M in fiscal 2025 and positive in 0 of the 10 years shown.
The diluted share count rose 655% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $52M | $64M | $58M | $51M | $44M | $17M | $4M | $2M | $2M | $2M |
| Gross profit | $44M | $45M | $58M | $53M | $47M | $39M | $15M | $2M | $2M | $1M | $1M |
| Operating income | -$343M | -$270M | -$172M | -$82M | -$79M | -$78M | -$63M | -$86M | -$59M | -$62M | -$43M |
| Net income | -$327M | -$266M | -$194M | -$81M | -$71M | -$7M | -$156M | -$86M | -$60M | -$63M | -$45M |
| EPS (diluted) | $-1.44 | $-1.42 | $-1.22 | $-1.02 | $-0.97 | $-0.98 | $-2.56 | $-1.91 | $-0.42 | $-2.20 | $-1.80 |
| R&D | $246M | $197M | $128M | $61M | $53M | $50M | $29M | $41M | $37M | $31M | $27M |
| Revenue growth | — | −18.5% | +9.0% | +13.5% | +18.3% | +150.1% | +311.7% | +112.4% | +3.5% | +1.9% | +7.8% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$253M | -$205M | -$135M | -$70M | -$60M | -$66M | -$54M | -$78M | -$49M | -$50M | -$34M |
| Capital spending | -$14M | -$12M | -$1M | -$6M | -$4M | -$1M | -$841000 | -$2M | -$2M | -$8M | -$2M |
| Free cash flow | -$267M | -$217M | -$136M | -$76M | -$63M | -$67M | -$54M | -$80M | -$51M | -$59M | -$36M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $57M | $43M | $33M | $18M | $17M | $15M | $8M | $9M | $7M | $7M | $6M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $737M | $392M | $196M | $102M | $164M | $228M | $54M | $54M | $42M | $68M |
| Debt | — | $77M | $76M | $74M | $36M | $33M | $34M | $35M | $25M | $18M | $16M |
| Equity | — | $654M | $315M | $91M | $35M | $88M | $76M | -$4M | $36M | $26M | $52M |
| Total assets | — | $808M | $458M | $252M | $149M | $205M | $262M | $79M | $73M | $55M | $75M |
| Shares (diluted) | 226M | 187M | 158M | 86M | 83M | 82M | 61M | 45M | 38M | 29M | 25M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 87.3% | 87.4% | 91.2% | 91.0% | 91.2% | 89.9% | 88.0% | 45.0% | 76.6% | 76.2% | 76.5% |
| Operating margin | -680.9% | -519.8% | -269.6% | -141.0% | -152.7% | -179.3% | -361.1% | -2029.9% | -2970.8% | -3220.1% | -2296.0% |
| Net margin | -648.6% | -511.9% | -303.7% | -138.1% | -137.9% | -15.1% | -894.3% | -2043.3% | -3014.0% | -3296.2% | -2369.0% |
| FCF margin | -530.0% | -417.5% | -213.4% | -130.6% | -123.0% | -153.4% | -312.6% | -1888.2% | -2568.6% | -3053.8% | -1903.5% |
| ROIC | — | -29.2% | -34.7% | -39.4% | -87.6% | -51.1% | -45.0% | -215.8% | -77.0% | -110.8% | -50.6% |
| ROE | — | -40.6% | -61.4% | -88.6% | -200.8% | -7.4% | -204.5% | 2379.4% | -167.2% | -242.4% | -86.0% |
Frequently asked questions
What is Ocular Therapeutix’s annual revenue?
$52M in fiscal 2025 and $50M over the twelve months to September 30, 2026.
How much profit does Ocular Therapeutix make?
Net income was -$266M in fiscal 2025 (net margin -511.9%).
Is Ocular Therapeutix’s revenue growing?
No: revenue fell 18.5% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.